# Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

> **NCT00131313** · PHASE4 · UNKNOWN · sponsor: **East Valley Hematology and Oncology Medical Group** · enrollment: 180 (—)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Nipent, Cytoxan, Rituxan

## Key facts

- **NCT ID:** NCT00131313
- **Lead sponsor:** East Valley Hematology and Oncology Medical Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2009-04
- **Target enrollment:** 180 (—)
- **Last updated:** 2005-08-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131313, "Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00131313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*